Weekly Charles River Laboratories International, Inc. (NYSE:CRL) Ratings as of May 16, 2018

May 16, 2018 - By Billy Entrekin

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.08. That’s change of 0.38, from 2017Q3’s 1.46. 35 investors sold all, 98 reduced holdings as Charles River Laboratories International, Inc. ratio turned negative. 104 increased holdings while 39 funds amassed holdings. Funds hold 44.57 million shares thus 0.83% less from 2017Q3’s 44.95 million shares.
Janney Montgomery Scott Limited Liability Com holds 6,213 shs. Commonwealth Of Pennsylvania School Empls Retrmt invested in 0.01% or 6,918 shs. Hodges Management Incorporated accumulated 51,961 shs or 0.42% of the stock. Gsa Cap Ltd Liability Partnership accumulated 31,931 shs. Moreover, Blair William & Il has 0% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Moreover, Teachers Retirement System Of The State Of Kentucky has 0.01% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Mai Capital Mngmt accumulated 10,222 shs. Arrowstreet Cap Limited Partnership invested 0.11% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Moreover, Grantham Mayo Van Otterloo Ltd Limited Liability Company has 0% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 3,500 shs. Moreover, Geode Mgmt Limited Liability Company has 0.02% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Savings Bank Of America Corporation De owns 450,612 shs for 0.01% of their capital. Manufacturers Life Insur The invested in 78,418 shs or 0.01% of the stock. Fil Limited holds 0.15% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL) for 488,609 shs. Cadence Cap Management Limited Com holds 0.12% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL) for 17,225 shs. Norris Perne French Llp Mi accumulated 100,295 shs or 1.6% of the stock.

Charles River Laboratories International, Inc. had 22 sales and 0 insider buys since January 2, 2018. This’s net activity of $10.95 million. On Tuesday, May 1 Smith David Ross sold $98,499 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 945 shs. 5,993 Charles River Laboratories International, Inc. (NYSE:CRL) shs with value of $646,703 were sold by FOSTER JAMES C. On Friday, March 9 $890,100 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by MILNE GEORGE M JR. Girshick Birgit had sold 9,893 shs worth $1.08 million on Tuesday, March 6. Barbo William D sold $250,741 worth of stock.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

A total of 10 analysts rate Charles River (NYSE:CRL) as follows: 5 “Buy”, 5 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NYSE:CRL) has 11 ratings reports on May 16, 2018 according to StockzIntelligence. In Tuesday, February 13 report Robert W. Baird maintained the stock with “Buy” rating. On Wednesday, February 14 the firm earned “Overweight” rating by JP Morgan. The stock rating was upgraded by SunTrust to “Buy” on Wednesday, February 14. On Tuesday, February 13 the stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Hold” rating by RBC Capital Markets. On Friday, April 20 the stock has “Hold” rating by MUFG Securities Americas Inc. The company rating was downgraded by SunTrust on Monday, January 22. The company rating was maintained by Jefferies on Tuesday, April 24. On Wednesday, March 14 Morgan Stanley maintained Charles River Laboratories International, Inc. (NYSE:CRL) with “Equal-Weight” rating. Listed here are Charles River Laboratories International, Inc. (NYSE:CRL) PTs and latest ratings.

24/04/2018 Broker: Jefferies Rating: Buy New Target: $129.0000 Maintain
20/04/2018 Broker: MUFG Securities Americas Inc Rating: Hold New Target: $115.0000 Initiate
20/04/2018 Broker: Mitsubishi UFJ Rating: Neutral New Target: $115 Initiates Coverage On
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $94 New Target: $102 Maintain
13/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $116.0 Maintain
13/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $123.0 Maintain
14/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $110 New Target: $120 Maintain
14/02/2018 Broker: SunTrust Old Rating: Hold New Rating: Buy Upgrade
22/01/2018 Broker: SunTrust Rating: Hold Downgrade
19/01/2018 Broker: Evercore Rating: In-Line New Target: $117 Initiates Coverage On

CRL reached $103.65 during the last trading session after $0.51 change.Charles River Laboratories International, Inc. has volume of 283,740 shares. Since May 16, 2017 CRL has risen 21.28% and is uptrending. The stock outperformed the S&P500 by 9.73%.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The firm is worth $4.97 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).40.86 is the P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

More recent Charles River Laboratories International, Inc. (NYSE:CRL) news were brought out by Globenewswire.com, Benzinga.com and Businesswire.com. The first one has “New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River …” as a title and was brought out on April 20, 2018. The next is “Earnings Scheduled For May 10, 2018” on May 10, 2018. And last was brought out on May 10, 2018, called “Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations”.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.